See more : Nahdi Medical Company (4164.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Protagonist Therapeutics, Inc. (PTGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protagonist Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- De La Rue plc (DLUEY) Income Statement Analysis – Financial Results
- Kaltura, Inc. (KLTR) Income Statement Analysis – Financial Results
- XBP Europe Holdings, Inc. (XBPEW) Income Statement Analysis – Financial Results
- Welsbach Technology Metals Acquisition Corp. (WTMA) Income Statement Analysis – Financial Results
- WiSA Technologies, Inc. (WISA) Income Statement Analysis – Financial Results
Protagonist Therapeutics, Inc. (PTGX)
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00M | 26.58M | 27.36M | 28.63M | 231.00K | 30.93M | 20.06M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.03M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 317.00K | 247.00K | 0.00 |
| Gross Profit | 60.00M | 25.55M | 24.58M | 28.63M | 231.00K | 30.93M | 20.06M | -317.00K | -247.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 96.12% | 89.86% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 120.16M | 126.22M | 126.01M | 74.51M | 65.00M | 59.50M | 46.18M | 25.71M | 11.83M | 7.46M |
| General & Administrative | 33.49M | 31.74M | 27.20M | 18.64M | 15.75M | 13.70M | 11.78M | 6.96M | 2.96M | 1.86M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.49M | 31.74M | 27.20M | 18.64M | 15.75M | 13.70M | 11.78M | 6.96M | 2.96M | 1.86M |
| Other Expenses | 0.00 | -80.00K | -149.00K | -46.00K | -1.00K | 0.00 | 0.00 | -34.00K | 0.00 | 0.00 |
| Operating Expenses | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M | 14.79M | 9.32M |
| Cost & Expenses | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M | 14.79M | 9.32M |
| Interest Income | 14.90M | 4.06M | 443.00K | 900.00K | 2.81M | 2.57M | 948.00K | 242.00K | 19.00K | 16.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 598.00K | 169.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.31M | 1.03M | 2.78M | 789.00K | 703.00K | 527.00K | 406.00K | 317.00K | 247.00K | 258.00K |
| EBITDA | -90.34M | -131.37M | -123.07M | -63.66M | -78.31M | -39.20M | -36.55M | -32.35M | -14.55M | -9.06M |
| EBITDA Ratio | -150.57% | -494.24% | -458.94% | -222.38% | -33,640.26% | -136.68% | -188.89% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.65M | -131.37M | -125.85M | -64.52M | -80.52M | -42.27M | -37.90M | -32.67M | -14.79M | -9.32M |
| Operating Income Ratio | -156.09% | -494.24% | -460.01% | -225.36% | -34,857.58% | -136.68% | -188.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.70M | 3.98M | 294.00K | -329.00K | 2.64M | 2.55M | 940.00K | -4.51M | -64.00K | -1.75M |
| Income Before Tax | -78.96M | -127.39M | -125.55M | -64.85M | -77.88M | -39.72M | -36.96M | -37.18M | -14.86M | -11.07M |
| Income Before Tax Ratio | -131.59% | -479.26% | -458.94% | -226.51% | -33,713.42% | -128.45% | -184.20% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.98M | -2.92M | 1.31M | -691.00K | -799.00K | -406.00K | 4.16M | 64.00K | 1.75M |
| Net Income | -78.96M | -123.41M | -122.63M | -66.15M | -77.19M | -38.92M | -36.96M | -37.18M | -14.86M | -11.07M |
| Net Income Ratio | -131.59% | -464.29% | -448.25% | -231.07% | -33,414.29% | -125.87% | -184.20% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| EPS Diluted | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| Weighted Avg Shares Out | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M | 5.88M | 5.88M |
| Weighted Avg Shares Out (Dil) | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M | 5.88M | 5.88M |
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the...
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.58 per share a year ago.
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative...
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at...
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity.
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports